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a b s t r a c t
Atypical parkinsonian disorders (APD) are a heterogenous group of neurodegenerative
diseases such as: progressive supranuclear palsy (PSP), multiple system atrophy (MSA),
cortico-basal degeneration (CBD) and dementia with Lewy bodies (DLB). In all of them core
symptoms of parkinsonian syndrome are accompanied by many additional clinical features
not typical for idiopathic Parkinson's disease (PD) like rapid progression, gaze palsy, apraxia,
ataxia, early cognitive decline, dysautonomia and usually poor response to levodopa
therapy. In the absence of reliably validated biomarkers the diagnosis is still challenging
and mainly based on clinical criteria. However, robust data emerging from routine magnetic
resonance imaging (MRI) as well as from many advanced MRI techniques such as: diffusion
weighted imaging (DWI) and diffusion tensor imaging (DTI), magnetic resonance spectros-
copy (MRS), voxel-based morphometry (VBM), susceptibility-weighted imaging (SWI) may
help in differential diagnosis. The main aim of this review is to summarize brieﬂy the most
important and acknowledged radiological ﬁndings of conventional MRI due to its availability
in standard clinical settings. Nevertheless, we present shortly other methods of structural
(like TCS – transcranial sonography) and functional imaging (like SPECT – single photon
emission computed tomography or PET – positron emission tomography) as well as some
selected advanced MRI techniques and their potential future applications in supportive role
in distinguishing APD.
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The term atypical parkinsonian disorders (APD) refers to a
heterogeneous group of neurodegenerative movement dis-
orders such as: progressive supranuclear palsy (PSP), multiple
system atrophy (MSA), cortico-basal degeneration (CBD) and
dementia with Lewy bodies (DLB). In all of them parkinsonism
is accompanied by additional features (not typical for
idiopathic Parkinson's disease) like rapid progression, gaze
palsy, apraxia, ataxia, early cognitive decline, dysautonomia
and usually poor response to levodopa therapy [1]. Although
the diagnosis is based on clinical criteria the differential
diagnosis at early stages is still challenging. It was shown in
the clinical-pathological studies that even 24% of the patients
with parkinsonian syndromes can be misdiagnosed [2].
Structural (magnetic resonance imaging – MRI or transcranial
sonography – TCS) or functional neuroimaging (single photon
emission computed tomography – SPECT or positron emission
tomography – PET) may enhance the accuracy of the clinical
diagnosis for parkinsonisms [3]. However, imaging studies are
not required to make a diagnosis of PD or APD (with exceptions
of regional cerebral blood ﬂow SPECT – rCBF SPECT – with
occipital hypometabolism as a supportive feature to conﬁrm
DLB [4] and MRI changes in recent Gilman's criteria for MSA
[5]). Computed tomography of the brain is generally not useful,
and may serve as a screening tool to rule out other pathologies
such as tumors, chronic subdural hematomas or normal
pressure hydrocephalus [6]. According to European Federation
of Neurological Societies (EFNS) guidelines routine 1.5 T MRI is
a method recommended to exclude symptomatic causes of
parkinsonisms, but it may be useful in differentiating PD from
APD [4,7]. TCS is another technique which has been proven to
be reliable and useful in the differential diagnosis of
parkinsonian syndromes [7]. All these structural imaging
methods can be supplemented by nuclear imaging techniques
(SPECT, PET), which provide additional information on brain
metabolism and perfusion [8].
2. Technical aspects of selected MRI
modalities
Two major kinds of MRI abnormalities seen in parkinsonian
syndromes are: atrophy – best seen in – T1W and changes of
tissue signal – in T2W [9]. The latter depends on the speciﬁcity
of the degenerational process. The accumulation of paramag-
netic substances (e.g. iron) triggers the decrease of signal,
which is observed, for example, in the basal ganglia due to the
accumulation of ferritin. These changes are best seen when
T2-weighted gradient-echo imaging is used, which indicates
that this sequence has a special diagnostic value for
parkinsonian disorders [10]. On the other hand, the increase
of the signal in T2-weighted images reﬂects the myelin
pathology such as Waller's degeneration, demyelinisation
and gliosis of white matter tracts which are seen as
hyperintensive changes [6].
As it has already been mentioned, this review focuses
mainly on routine MRI as it is considered a basic ancillary test
in diagnosing APD [2]. However, some advanced techniquesare mentioned and characterized here shortly as well, since a
lot of recent reports highlighted their growing role in
diagnosing APD. At present, these techniques are still being
evaluated and are not used in clinical practice, but we can
expect a robust progress in that ﬁeld in the near future. The
most common are: diffusion weighted imaging (DWI) and
diffusion tensor imaging (DTI), magnetic resonance spectros-
copy (MRS), voxel-based morphometry (VBM), susceptibility-
weighted imaging (SWI) [11]. DWI and DTI are techniques
based on the random movement of water molecules, which is
increased in the degenerated tissues due to the distraction of
ﬁbers, which in normal conditions limits the process of
diffusion [1]. Quantiﬁcation of diffusion is performed by
calculation of the apparent diffusion coefﬁcient (ADC) [12].
SWI is a new MRI technique which exploits the magnetic
properties of iron content in tissues [13]. VBM is an operator
independent, semi-automated technique which allows to
assess quantitatively the regional cerebral atrophy [14]. H-
MRS allows to monitor biochemical structure of tissues in vivo.
It is based on the analysis of the ratio of metabolites such as:
NAA (N-acetylaspartate) – as a marker of cells integrity, Cho
(choline) – which is a phospholipid involved in the cells'
membranes synthesis and a marker of their disintegrity, Cr
(creatine) – marker for energy metabolism and myo-Ins (myo-
inositol), which is a marker of glial cells with increased levels
being associated with gliosis [8,14].
In general, it is considered that the conventional 1.5 T MRI
images of PD patients, including T1W (T1-weighted images),
T2W (T2-weighted images), T2 FLAIR (Fluid Light Attenuation
Inversion Recovery) and proton density sequences do not
show any abnormalities and do not differ from the controls
[15,16]. Nevertheless, a lot of the characteristic radiological
features have been described, which help to distinguish PD,
PSP, MSA and CBD patients, some of them have their
acknowledged position in supporting the clinical diagnosis
and can be quite easily used in everyday radiological practice.
This short review aims to summarize the most important,
evidenced radiological signs of APD. The utility of those signs
is assessed with the use of terms such as: sensitivity,
speciﬁcity and positive predictive value. Sensitivity is the
proportion of true positives – patients with the disease and
with the abnormal ﬁnding in the radiological imaging.
Speciﬁcity is the proportion of true negatives – healthy people
without the abnormal ﬁndings in MRI. The positive predictive
value (PPV) is the likelihood of the person with the abnormal
ﬁnding in MRI to have the disease [17]. This review
summarizes neuroimaging methods helpful in differential
diagnosis of APD, and is mostly focused on standard MRI
protocols as the method is used commonly in everyday
practice.
3. Atypical parkinsonian syndromes
3.1. Progressive supranuclear palsy
PSP known also as Steele–Richardson–Olszewski disease is the
most common of the parkinsonian taupathies [18] with a
prevalence of 0.97–6.54 cases per 100 000 [19]. Its classical
variant, called Richardson syndrome, PSP-RS, is characterized
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supranuclear gaze palsy, dysarthria, axial rigidity, symmetric
bradykinesia and dementia with pronounced frontal syn-
drome [20,21]. In the recent years several other phenotypic
variants of PSP, varying in the clinical features, severity and
pattern of atrophy have been described: PSP-PAGF (pure
akinesia with gait freezing), PSP-PNFA (PSP with progressive
non-ﬂuent aphasia), PSP-C (PSP-cerebellar), PSP-CBS (PSP-
corticobasal syndrome) [22]. Neuronal degeneration in PSP
affects many areas of the brain: midbrain, superior cerebellar
peduncle [23–25], subthalamus, pallidum, dentate nucleus,
frontal lobes [26]. The radiological abnormalities are related to
these pathological ﬁndings [27]. The midbrain atrophy with
the enlargement of the third ventricle is regarded as the
neuropathological hallmark of PSP [28] (Fig. 1A). The atrophy of
the midbrain with the preservation of the pons constitutes a
speciﬁc pattern resembling a humming bird or a penguin and
is known as the ‘‘humming bird sign’’ (HBS) [6,29], sometimes
also called the ‘‘penguin silhouette sign’’, which are seen on
midsagittal section [30] (Fig. 1B). According to the study of
Massey et al. [31] the HBS has a very high speciﬁcity (100%) and
PPV for a pathological diagnosis, but much lower sensitivity
(68%). It is evidenced that smaller size of the midbrain area is
associated with faster clinical progression [32]. To be more
precise and objective linear or surface morphometric evalua-
tions may be used. The midbrain atrophy can be assessed by
measuring its anterior–posterior diameter on sagittal images
(cut off value 11.6 mm) [28]. The midbrain area can also be
measured in sagittal projection and the value ≤105 mm2
indicates the diagnosis of PSP [33]. Oba et al. [30] suggest that
value <70 mm2 strongly indicates PSP. The latter parameter
permits to discriminate between PSP and control patients with
100% of sensitivity, however speciﬁcity is lower due to the
overlap with some MSA-Parkinsonism (MSA-P) patients [28].
The SCP (superior cerebellar peduncle) width is the next
radiological parameter proved to be reduced in many studies
[34] with the cut-off value ≤3.0 mm (measured on axial images)
as proposed by Gama et al. [33] (Fig. 2A). It was observed that
SCP width showed the largest reduction in the consecutive MRI
examinations – performed within less than 2 years after initialFig. 1 – The atrophy of midbrain with the enlargement of the th
periaqueductal area (A, axial T2W); ‘‘humming bird sign’’ in PSPMRI, which suggests its utility in monitoring the progression of
the disease [34].
However, there is a lack of clear conclusions from studies
how early in the disease course the MRI ﬁndings typical for PSP
diagnosis occur, clinical experience and indirect data from
recent studies suggest they are rather late. In the study of Kim
et al. [35], MRI midbrain tegmentum diameter was shortened
in PSP patients, but mean time from disease onset to MRI
examination was 4.09 years.
In order to differentiate between PSP and MSA-P patients
who share some of the radiological features, Quattrone et al.
[36] proposed a combination of these measurements by
counting MCP/SCP ratio (middle/superior cerebellar peduncle)
and P/M ratio (pons/midbrain) (Fig. 2B). Since both SCP and M
are reduced in PSP, these two values are higher among PSP
patients in comparison to MSA-P or PD.
Another parameter which may help to distinguish the
group of PSP patients is the higher MR parkinsonism index,
which is calculated according to: [(P/M)  (MCP/SCP)]. Accord-
ing to Quatrone MR parkinsonism index distinguishes patients
with PSP from PD, MSA-P and healthy controls with 100%
speciﬁcity and sensitivity and 100% of PPV. This parameter can
be useful not only in the process of diagnosis, but it can also be
a good marker of the disease progression [36].
In PSP the changes of signal in degenerated tissues, such as
T2W hyperintensities in the tegmentum, tectum [37] and
periaqueductal area [16] were also reported. In DWI MRI
studies greater ADC values of the SCPs were evidenced in
comparison to PD patients or healthy controls [38]. DTI studies
revealed widespread white matter degeneration in PSP.
Abnormalities were seen in the body of corpus callosum,
cingulate gyrus, associative ﬁbers: superior and inferior
longitudinal fasciculi and SCPs – in which diffusion changes
correlated strongly with clinical disease severity [39]. VBM MRI
studies revealed the cortical atrophy in frontal and parietal
lobes [40], precise manual measurements proved reductions
also in the striatum – caudate nucleus and putamen [41].
The data on the utility of MRI in differentiation between PSP
subtypes is very limited. Longoni et al. [42] showed a relatively
smaller involvement of infratentorial brain in PSP-P comparedird ventricle and hyperintensities of signal in the
 patient (B, sagittal T1W).
Fig. 3 – The rCBF SPECT examination of PSP patient showing
hypoperfusion of frontal lobes.
Fig. 2 – Measurements of SCP (superior cerebellar peduncle) (A, axial T2W); measurements of midbrain and pons area
(B, sagittal T1W) in a PSP case.
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study, which showed that midbrain area is not reduced in PSP
patients who have atypical clinical presentation. It indicates
that midbrain atrophy can be a marker of RS but, on the other
hand, the lack of its atrophy does not exclude a pathological
diagnosis of PSP. These two studies have also found a
correlation between subtle midbrain atrophy in PSP-PNFA,
with subsequent symptoms of classic RS. It suggests that
midbrain volume reduction can indicate probable future
development of RS symptoms.
TCS is another non-invasive tool supportive for PSP
diagnosis. It is recommended by EFNS for differential diagno-
sis of PD from APD and secondary parkinsonian syndromes [7].
The normoechogenicity of substantia nigra (SN) is a ﬁnding
typical for PSP and MSA patients, whereas in PD SN is
hyperechogenic [44,45], but lenticular nucleus (LN) hypere-
chogenicity is characteristic for PSP and MSA, but not PD
patients. It was evidenced that marked, at least unilateral SN
hyperechogenicity in combination with normal LN echogeni-
city differentiates PD from PSP and MSA patients with a PPV
>90% [45,46]. TCS can also support the differentiation between
PSP and CBD. In study of Walter's [47] the combination of
marked SN hyperechogenicity and third-ventricle width
<10 mm indicated CBD with a sensitivity of 83%, a speciﬁcity
of 100%, and a PPV of 100%.
Functional neuroimaging techniques are also useful in PSP
diagnosis. In many SPECT and FDG-PET studies hypoperfusion
and hypometabolism in the frontal lobes (typically posterior)
(Fig. 3), striatum, thalamus and midbrain [8] were observed in
PSP patients.
FDG-PET study of Srulijes group evidenced the difference in
metabolism between PSP-RS (pronounced frontal and thalam-
ic hypometabolism) and PSP-P patients (pronounced putam-
inal hypometabolism) [48].
PET imaging with 2-(1-{6-[(2-[F-18]ﬂuoroethyl)(methyl)ami-
no]-2-naphthyl}ethylidene)malononitrile [F-18] FDDNP probe,
which enables the visualization of pathological hyperpho-
sphorylated tau deposits in living brains, is another promising
technique. This method detects tau aggregates in subcorticaland cortical areas with the pattern speciﬁc only to PSP,
regardless of its clinical variability. Presumably, this technique
may be helpful not only as a valuable diagnostic tool for all PSP
phenotypes, but also in future as an indicator of treatment
efﬁcacy [49].
3.2. MSA
MSA is a member of the group of neurodegenerations called
alpha-synucleinopathies. Its prevalence rates range between
1.9 and 4.9 per 100 000 [50]. The major neuropathology consists
of degeneration of the nigrostriatal and olivopontocerebellar
structures [5]. Clinically the disease is manifested by:
parkinsonian syndrome, autonomic dysfunction (orthostatic
hypotension, erectile dysfunction, urinary incontinence and
constipation), and cerebellar signs [5]. According to the
predominance of clinical features MSA consists of two forms:
MSA-P – with predominant parkinsonism (80% of patients) and
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accompanied by dysautonomia in both subtypes [51]. These
two clinical variants also differ in terms of brain areas involved
in the pathological process – in MSA-C neurodegeneration
affects predominately brainstem and cerebellum and in MSA-P
basal ganglia, particularly the putamen are involved [6,52].
Typical radiological features observed in MSA-P are:
hyperintense putaminal rim, putaminal atrophy and hypoin-
tensity, atrophy and signal decrease of the globus pallidus and
infratentorial signal increase and atrophy. The involvement of
the infratentorial structures is more speciﬁc for MSA-C. In
MSA-C the most characteristic changes are: atrophy of the
middle cerebellar peduncle, the dilatation of 4th ventricle,
atrophy of pons, increased signal within the cerebellum,
middle cerebellar peduncles and pons [15,53]. However, it was
documented that radiological ﬁndings considered to be more
typical of MSA-P, such as putaminal atrophy, are also found in
the clinical MSA-C cases and, conversely MSA-P patients may
present cerebellar signs. It was proven that these cerebellar
ﬁndings in MSA-P patients can still be highly speciﬁc for the
diagnosis of MSA-P when compared to PD (90–100%), but are
less sensitive (14–71%) [54]. The supratentorial abnormalities
were observed more often and earlier in MSA-P and conversely
the infratentorial appeared more often and earlier in MSA-C
patients [55].
It is evidenced that both MSA phenotypes share the
common pathological process, which explains the overlap of
clinical symptoms and radiological signs between them. The
atrophy of the putamen, middle cerebellar peduncle and pons
or cerebellum in both MSA forms is enclosed in the revised
diagnostic criteria of MSA [5].
T2-weighted hyperintensities may be helpful in making
diagnosis. Savoiardo evidenced the presence of signal hyper-
intensities in the pons, middle cerebellar peduncles, and
cerebellum among MSA patients [56]. The signal increase in
MCPs was proven to be a useful parameter in diagnosing MSA-
C with the high speciﬁcity (100%) and sensitivity (85.2%) in
comparison to PD, PSP patients and controls [38,57]. The
increased signal within the basis pontis, caused by the
degeneration of the pontine neurons and transverse ponto-
cerebellar ﬁbers with the preservation of corticospinal tracts,
forms a radiological hallmark for MSA called ‘‘hot-cross bun’’
(Fig. 4A). It can be seen on transverse T2W images of the brain
as a cruciform hyperintensity in the pons [52]. The ﬁnding was
reported to have a very high speciﬁcity and PPV (97%), but low
sensitivity (50%) [15] in differentiating MSA from PD and PSP.
Nevertheless, although the ‘‘hot cross bun’’ sign is typical, it is
not pathognomonic to MSA [58]. The ﬁnding has also been
observed in cases of spinocerebellar ataxia (SCA) types 2 and 3
and brainstem vasculitis [59]. The presence of a cruciform
hyperintensity is correlated with the duration of the disease,
which indicates that this sign may serve as a parameter for
measuring the disease progression [59].
The common observation in MSA patients is the hypoin-
tensity of the basal ganglia on T2-weighted MRI images,
frequently with lateral putaminal hyperintensivity, which
reﬂects the degeneration of putamen [60–62]. It may be
considered as another radiological sign of MSA called the
‘‘putaminal hyperintense rim’’ (HPR) (Fig. 4B–E). It was
reported as having 100% speciﬁcity and positive predictivevalue in MSA-P versus PD and controls at 1.5 T [53].
Nevertheless, it should be mentioned here that at a high
magnetic ﬁeld strength the HPR sign is not an exclusive
hallmark of MSA, but it is considered to be a normal ﬁnding in
3 T MRI in healthy subjects [60,63].
All these signal abnormalities generally become more
pronounced with the disease's progression. In a longitudinal
MRI study of Horimoto et al. [64] the pontine ‘‘hot cross bun’’
sign was completed mainly before 5 years from the symptoms
onset in MSA-C patients, and even later in MSA-P. The HPR
sign appeared as bilateral changes within 3–6 years in MSA-P
cases, in MSA-C at least 4 years were required even for
unilateral changes of signal to be detected [64].
Several histopathological studies revealed increased iron
concentration in the putamen, which correlates with MRI
ﬁndings in iron-sensitive sequences like T2*-GRE [10], which
allowed to differentiate MSA from PD patients accompanied
with SWI technique, in which much higher iron deposition
was observed in the putamen of MSA-P as compared to PD [13].
In everyday radiological practice some morphometric
studies can also be easily conducted and used as supportive
diagnostics of MSA, e.g. the measurement of the pons,
whereby an area <315 mm2 in the sagittal projection indicates
its atrophy and the diagnosis of MSA-C with a positive
predictive value of 72.7% [33].
The reduction of the MCP width may support the previous
ﬁndings showing pontocerebellar atrophy as the pathological
hallmark of the disease.
The average width of the MCP was signiﬁcantly smaller in
patients with MSA than in those with PD or control subjects. In
accordance to Nicoletti et al. [65] the width of MCP is a
parameter which helps to distinguish between patients with
MSA from those with PD with a sensitivity of 100%, a speciﬁcity
of 100%, and a positive predictive value of 100%. The proposed
cut off value is ≤8 mm in the sagittal projection [65].
A signiﬁcant difference in the average width of MCP was
observed between the two groups: patients with ‘‘hot-cross
bun sign’’ had the MCP width signiﬁcantly smaller, which
conﬁrms a correlation between the presence of cruciform
hyperintensity and severe atrophy of the MCP [65].
DWI MRI images revealed enhanced values of rADC
coefﬁcients in the putamen of the MSA-P patients in
comparison to PD, which allows to differentiate these diseases
[66]. Abnormal diffusity measures were also reported in MCP
[65,67], cerebellum [67], pons [68]. A prospective study of
Pellecchia et al. [69] revealed that abnormal diffusity in the
putamen increased over time and can be a marker of the
disease progression.
FDG-PET studies in MSA have shown decreased glucose
metabolism in the putamen, brainstem and cerebellum and
their results were incorporated into Gilman's MSA criteria [5].
The role of TCS in diagnosing MSA was discussed earlier.
3.3. CBD
CBD is another, but less common and probably under-
diagnosed taupathy [70,71]. The true incidence of the disease
is unknown [72]. The pathological changes are localized
predominantly in the frontoparietal cortex, basal ganglia
and substantia nigra [70]. The disease presents usually with
Fig. 4 – The ‘‘hot cross-bun sign’’ in MSA-C case (A, axial T2W); the images of putaminal hypointensity and ‘‘slit-like’’
marginal hyperintensities with ‘‘hyperintense putaminal rim’’ HPR sign (axial T2W) in 4 different MSA-P patients (B–E).
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tions which include both: cortical dysfunction (apraxia, 'alien
limb' phenomena, cortical sensory loss, myoclonus, mirror
movements, aphasia or hemispatial neglect) and basal ganglia
dysfunction (bradykinesia, progressive asymmetric rigidity,
dystonia, tremor) totally not levodopa responsive [73]. The
clinical diagnosis of CBD is challenging due to its asymmetrical
onset accompanied by upper limb apraxia, often misdiagnosed
(limb-kinetic apraxia interpreted as bradykinesia) as PD. The
typical clinical presentation of CBD may be presented bydifferent underlying pathologies as Alzheimer's, PSP or even
Creutzfeldt–Jakob disease. Therefore, recently the term corti-
cobasal syndrome (CBS) has been proposed to cover the broad
pathology comprising the clinical syndrome [74]. Obviously, it
may complicate establishing a uniform neuroimaging pattern
of this syndrome. Routine brain MRI usually shows asymmet-
ric atrophy in the fronto-parietal regions and asymmetric
enlargement of the lateral ventricles contralateral to the more
affected side [75,76]. The T2-weighted MRI images of patients
with CBD revealed signiﬁcant signal hypointensity in the
Fig. 6 – rCBF SPECT of DLB patient showing the
hypoperfusion of occipital lobes.
Fig. 5 – rCBF SPECT of CBS patient with unilateral,
asymmetric hypoperfusion.
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changes in the motor cortex or subcortical white matter
[56,78]. On diffusion-weighted MRI images (DWI) a signiﬁcant
difference in rADC coefﬁcients between extensive hyperin-
tensity in the frontoparietal white matter can be observed,
especially on the predominant side of cortical atrophy [38]. DTI
studies revealed degeneration of motor pathways, especially
the corticospinal tracts, which may explain the presence of
pyramidal symptoms among some CBS patients [79]. Cortico-
subcortical atrophy is contralateral to the side of the body
most affected clinically, but at the early stages it may be not so
evident and the early asymmetry may be better detected by
rCBF SPECT (Fig. 5) or PET unilateral hypoperfusion [80].
3.4. DLB
DLB is a synucleinopathy and the second most common
disorder among neurodegenerative dementias after Alzhei-
mer's disease (AD) [81]. The prevalence is estimated as 3.8–
4.5% of all diagnosed dementias [82]. DLB is characterized by
dementia with ﬂuctuations of cognitive status, visual hallu-
cinations and parkinsonian signs (bradykinesia, rigidity,
tremor) [83], as well as hypersensitivity to neuroleptics [4],
which occurs in 30–50% of patients [82].
The pathological process affects brain stem nuclei and
many other areas, such as limbic and neocortical regions [4].
The disease clinically is often confused with other dementias,
usually AD and PD. Although there are formal clinical criteria
[4] the differentiation can be often difﬁcult because of clinical
overlaps between these disorders and potential difﬁculties to
diagnose dementia preceding parkinsonism, which is the core
feature of DLB. It has been shown that in MRI of DLB patients
the mesial temporal lobe (especially the hippocampus) is
relatively preserved in comparison to AD [84–87]. MRI VBM
studies showed the signiﬁcant involvement of subcortical
regions with striatal and putaminal atrophy [84,88].DLB diagnosis may be improved if supported by functional
imaging as PET and SPECT [89]. In DLB the hypoperfusion of the
occipital lobes have been reported in PET and SPECT studies
[90,91] (Fig. 6). The real cause of this observation is not clear,
what is more, the majority of VBM MRI analyses did not show
any relation to the structural changes in occipital lobes [84,92].
4. Conclusions
There has been a remarkable progress in the neuroimaging
techniques in atypical parkinsonism in the recent years.
Neuroimaging results can strongly support the clinical diagno-
sis which is crucial for the prospective care planning.
Nevertheless, the increasing data on mixed pathologies and
overlapping clinical presentations of those disorders (different
presentations of PSP with classical Richardson syndrome in
only 50% of cases or CBS covering wide spectrum of pathologies)
makes the precise differentiation difﬁcult (Table 1).
Furthermore, those radiological markers or hallmarks in
many APD are usually rather late ﬁndings, so their utility for
earlier diagnosis and possible medical interventions may be
questionable. Those regarded as typical ﬁndings may be visible
only with the use of special MRI sequences and the standardized
protocols e.g. instituted by NNIPPS (Neuroprotection and
Natural History in Parkinson's Plus Syndromes), which was
intended to measure disease severity and progression in
multicentre clinical trials (Table 2). The diagnosis of the APD
can be improved both by applying new MRI techniques and
modifying conventional sequences. The use of 3 or 7 T MRI
scanners will probably strengthen the diagnostic value too, but
they are not widely available and the use of 7 T is still
controversial in humans [2]. Although there is a lack of effective
treatments of APD, the biomarkers revealing subtle changes,
which are able to predict the clinical diagnosis may be valuable
in case of the availability of disease-modifying therapies.
Table 1 – Characteristic features of brain MRIs in Parkinsonian disorders (according to Sitburana and Mahlknecht) [40,93].
Atrophy
of
midbrain
Pons and
cerebellum
atrophy
Putaminal
atrophy
Cortical
atrophy
rADC" Special
signs
Low
values of
M/P ratio
High
values
of MRPI
PD +  + +    +
PSP +++ +  ++ ++putamen
+++SCP
HBS +++ +++
MSA-P ++ ++ +++ + +++putamen PRH + 
MSA-C + +++ + + + HCB sign  
CBD +   +++  Asymmetry  
DLB   + +    
PD – Parkinson's disease; PSP – progressive supranuclear palsy; MSA-P – multiple system atrophy-parkinsonian type; MSA-C – multiple system
atrophy-cerebellar type; CBD – corticobasal degeneration; DLB – dementia with Lewy bodies; rADC – regional apparent diffusion coefﬁcient; HBS
– ‘‘hummingbird sign’’; PRH – ‘‘putaminal rim hyperintensity’’; HCB – hot cross bun sign; SCP – superior cerebellar peduncles; M/P – midbrain/
pons; MRPI – MR parkinsonism index [(P/M)  (MCP/SCP)]; MCP – middle cerebellar peduncles.
Table 2 – NNIPPS imaging protocol for Parkinson's plus syndromes according to Rolland et al. [27].
Plane Acquisition Slice Number
of slices
Filma TR (ms) TE (ms) FOV (mm) Matrix
Sagittal FGE T1 weighted 5 16 1 250–512 14–16 230–240 512  (224–256)
Axial bicallosal plane FSE proton density 3 40 2 5270–6000 12–20 230–240 256  (224–256)
Axial bicallosal plane FSE T2 weighted 3 40 2 5270–6000 75–110 230–240 256  (224–256)
Coronal orthogonal to
the bicallosal plane
FSE T2 weighted 3 40 2 4520–5200 96–110 230–240 512  (204–256)
Axialb 3D IR T1 weighted 0.9 160 2c 2500IT = 500 Minimum 230–230 256  256
3D – three dimensional; FGE – fast gradient echo; FOV – ﬁeld of view; FSE – fast spin echo; IR – inversion recovery; TE – echo time; TR – repetition
time; NNIPPS – Neuroprotection and Natural History in Parkinson's Plus Syndromes.
a Printed ﬁlms contain 20 images each.
b The whole cerebrum including the cerebellum and brainstem.
c Reconstruction of 20 slices at 5 mm thickness in the bicallosal plane, centered on the basal ganglia.
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